Diagnostics

A peer-reviewed case report in Catheterization and Cardiovascular Interventions shows hybrid IVUS-OCT imaging identified post-stent dissections and thrombus missed by

Sol-Gel Technologies has completed patient follow-up in its Phase 3 patidegib gel study, with top-line results expected in late November 2026.

A retrospective study of 345 paired tests found 83.5% of patients on RestoreU showed stable or improved cognition over 14 months.

Updated NCCN multiple myeloma guidelines establish a dedicated MRD framework and specifically name Adaptive Biotechnologies' clonoSEQ as an FDA-cleared assay.

The Gates Foundation-funded collaboration will run field studies in Kenya, integrating Sonus's autonomous ultrasound patch with Medtronic's patient monitoring platform.

Senseonics and Beta Bionics plan to integrate the year-long implantable CGM with the iLet Bionic Pancreas, targeting a commercial launch in Q4 2026.

The Palo Alto radiosensitizer biotech said its UK-led breast cancer study is now moving toward a 2027 efficacy readout, as two further cancer trials

The Atlanta-based biotech enrolled 239 patients at the top of its target range, with topline data expected in November 2026.

Updated SOLARA Phase 1/2 data show an 88% disease control rate in a resistance population with no approved targeted therapies.

BioVie reported statistically significant improvements in Long COVID patients with high symptom burden, with Phase 3 now planned for bezisterim.

Three peer-reviewed studies across the US, Finland, and Spain show optical genome mapping uncovers clinically actionable variants missed by standard karyotyping.

The Saudi specialist healthcare group used the Forbes Middle East Healthcare Summit 2026 to set out its expansion plans and tout a first-in-world

Agomab's lung-restricted ALK5 inhibitor showed favourable safety and proof-of-mechanism in IPF patients; a Phase 2 study is set to begin before

Telix Pharmaceuticals has secured FDA approval for Pixclara, the first radiopharmaceutical PET imaging drug cleared in the US for glioma diagnosis.

Veracyte is adding the UroAmp urinary tumour DNA platform to its bladder cancer portfolio, with commercialisation targeted for late 2028.

Femasys has linked with specialist fertility lender CapexMD to offer patients financing for its FemaSeed intratubal insemination portfolio across OB/GYN practices.

A new methodological scoping review by Persica Pharmaceuticals argues that low assay sensitivity explains conflicting findings on bacterial presence in spinal discs.

The Danish cell-counting specialist reported DKK 511m in revenue and a 55% EBITDA margin for 2025/26, with automation demand accelerating instrument sales.

Nano-X Imaging grew Q2 revenues to $4.2m but recorded a $40.7m intangible asset impairment, widening its GAAP net loss to $55.5m.

Quantum BioPharma has FDA clearance to begin a Phase 2 trial of Lucid-MS, a PAD2 inhibitor designed to target demyelination rather than suppress the